. Author manuscript; available in PMC: 2023 Jul 1.

Published in final edited form as: J Natl Compr Canc Netw. 2022 Jul;20(7):783–791.e1. doi: 10.6004/jnccn.2022.7008

Table 1.

Baseline characteristics and treatment details, unmatched and matched cohort.

	Unmatched cohort				Matched cohort
	Overall	No radiotherapy	Radiotherapy	P-value	Overall	No radiotherapy	Radiotherapy	P-value
	n = 424	n = 229	n = 195		n = 300	n = 150	n = 150
Female, n (%)	189 (44.6)	92 (40.2)	97 (49.7)	0.06	147 (49.0)	72 (48.0)	75 (50.0)	0.82
Age, years (median [IQR])	64 [57, 70]	64 [58, 69]	64 [57, 70]	0.85	64 [57, 70]	65 [58, 70]	64 [57, 70]	0.57
Performance status, n (%)				<0.001^*				0.91
WHO 0	222 (52.4)	139 (60.7)	83 (42.6)		150 (50.0)	76 (50.7)	74 (49.3)
WHO 1	202 (47.6)	90 (39.3)	112 (57.4)		150 (50.0)	74 (49.3)	76 (50.7)
BMI, kg/m² (median [IQR])	26 [23, 29]	26 [23, 30]	26 [24, 29]	0.78	26 [24, 30]	26 [23, 30]	26 [24, 29]	0.77
Tumor location: Head/uncinate, n (%)	335 (79.0)	184 (80.3)	151 (77.4)	0.54	229 (76.3)	117 (78.0)	112 (74.7)	0.59
Tumor size on CT, mm (median [IQR])	34 [26, 41]	33 [26, 41]	34 [27, 43]	0.29	34 [27, 41]	34 [26, 41]	34 [27, 41]	0.58
Pre-treatment CA 19–9, U/mL (median [IQR])	196 [48, 653]	178 [42, 578]	232 [75, 706]	0.13	198 [46, 653]	157 [30, 582]	238 [73, 710]	0.14
Number of cycles, n (%)				0.001^*				0.88
1–4 cycles	142 (33.5)	95 (41.5)	47 (24.1)		92 (30.7)	48 (32.0)	44 (29.3)
5–8 cycles	230 (54.2)	109 (47.6)	121 (62.1)		172 (57.3)	84 (56.0)	88 (58.7)
>8 cycles	52 (12.3)	25 (10.9)	27 (13.8)		36 (12.0)	18 (12.0)	18 (12.0)

^{* =}

significant p-value <0.05.

Abbreviations: BMI, body mass index; CA 19-9, carbohydrate antigen 19-9; CT, computed tomography; IQR, interquartile range; n, number; WHO, World Health Organization. Missing data: BMI (n=6), tumor size (n=12), CA 19-9 (n=31).